Phenylketonuria (also called PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2880291-phenylketonuria-pku-pipeline-review-h1-2018
Top Companies mentioned
American Gene Technologies International Inc
BioMarin Pharmaceutical Inc
Censa Pharmaceuticals Inc
Erytech Pharma SA
Synthetic Biologics Inc
Ultragenyx Pharmaceutical Inc
Phenylketonuria (PKU) Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Phenylketonuria (PKU) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Phenylketonuria (PKU), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
It also reviews key players involved in Phenylketonuria (PKU) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 1 and 4 respectively.
Phenylketonuria (PKU) - Competitive Analysis
Key players are making innovative developments in Phenylketonuria (PKU) industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The report provides a snapshot of the global therapeutic landscape for Phenylketonuria (PKU)
The report reviews Phenylketonuria (PKU) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved in Phenylketonuria (PKU) targeted therapeutics and enlists all their major and minor projects.
The report assesses Phenylketonuria (PKU) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2880291-phenylketonuria-pku-pipeline-review-h1-2018
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
P: +44 208 133 9349
M: +1 646 845 9349